Confident Investing Starts Here:
- Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
Shanghai Junshi Biosciences Co., Ltd. Class H ( (HK:1877) ) has shared an announcement.
Shanghai Junshi Biosciences Co., Ltd. has announced its participation in the 2024 Annual Results Briefing for the STAR Market Innovative Drug Sector and the 2025 First Quarterly Results Briefing. This event, scheduled for May 8, 2025, aims to provide investors with a comprehensive understanding of the company’s operating results and financial status for 2024 and the first quarter of 2025. The briefing will be held online, allowing investors to engage interactively and submit questions in advance. This initiative is expected to enhance transparency and strengthen investor relations, potentially impacting the company’s market positioning and stakeholder engagement.
More about Shanghai Junshi Biosciences Co., Ltd. Class H
Shanghai Junshi Biosciences Co., Ltd. is a biopharmaceutical company based in China, primarily focused on the development and commercialization of innovative drugs. The company operates in the pharmaceutical industry, with a market focus on innovative drug development, particularly for the STAR Market.
YTD Price Performance: 38.00%
Average Trading Volume: 2,229,121
Technical Sentiment Signal: Sell
Current Market Cap: HK$28.02B
Find detailed analytics on 1877 stock on TipRanks’ Stock Analysis page.